JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 176 filers reported holding JUNO THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $19,000 | 0.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $19,000 | -13.6% | 500 | 0.0% | 0.00% | -25.0% |
| Q4 2015 | $22,000 | +10.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $20,000 | -25.9% | 500 | 0.0% | 0.00% | -20.0% |
| Q2 2015 | $27,000 | -10.0% | 500 | 0.0% | 0.01% | -16.7% |
| Q1 2015 | $30,000 | – | 500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |